Benchling: acquisition of Overwatch Research
R&D cloud software provider Benchling acquired Overwatch Research, a startup offering software intended to accelerate in vivo research. The move is intended to create a comprehensive, cloud-native in vivo solution for customers.
“Our software tackles core challenges contributing to the preclinical reproducibility crisis. This helps biopharmaceutical companies and contract research organizations (CROs) reduce errors, increase confidence for first-in-human studies, and ultimately get drugs to patients faster," said Chris Armstrong, co-founder and CEO of Overwatch. “By incorporating our in vivo study capabilities into Benchling’s industry-leading R&D Cloud, we’ll be able to reach more scientists and help them turn initial research findings into life-saving products.”